FOR IMMEDIATE RELEASE
MESA, Ariz. — December 22, 2022
Recently our researchers discovered some very novel practices being undertaken in China, where Uterine Artery Embolization (UAE), which is usually reserved for the treatment of Uterine Fibroids, is being used to treat Cesarean Scar Ectopic Pregnancies (CSP). We assembled the data we could find to offer this interesting look into these novel procedures taking place in China. The full paper is published online and can be viewed free of charge at the publisher’s website. the abstract can also be found on the US Government’s PubMed Website.
About the Marchand Institute for Minimally Invasive Surgery
The Marchand Institute for Minimally Invasive Surgery is a 501(c)(3) tax-exempt non-profit research and educational institution based in Mesa, Arizona (EIN 42-2857240). The Institute produces peer-reviewed systematic reviews and meta-analyses in minimally invasive gynecologic surgery and women’s health, conducts FDA clinical trials, and trains surgeons through an SLS-accredited fellowship. All reviews are prospectively registered with PROSPERO, reported to PRISMA standards and appraised using the Cochrane RoB 2 tool. The Institute accepts no pharmaceutical or medical device industry funding and declares no conflicts of interest. It is directed by Greg J. Marchand, MD, FACS, FACOG, FICS.
Media Contact
Maria A. Sainz, Director of Communications and Media Relations
Marchand Institute for Minimally Invasive Surgery
maria@marchandobgyn.com | (480) 999-0905
Interview requests, expert commentary topics, boilerplate and high-resolution images: Newsroom & Press Kit. Complete publication record with DOIs and PMIDs: Publications database. Methodology: How we run a review.
###